Tumor stage (stage 2: HR = 2.2 [1.2–3.8], p = 0.006; stage 3: HR = 4.4 [2.1–8.3], p < 0.0001), ER status (negative: HR = 1.3 [0.96–2], p = 0.08), and HER2 metagene score (positive: HR = 1.4 [1.02–2.1], p = 0.04) were significant prognostic factors (p < 0.1). The gene discussed is ERBB2; the disease is neoplasm.